Berenson R J, Bensinger W I, Hill R, Andrews R G, Garcia-Lopez J, Kalamasz D F, Still B J, Buckner C D, Bernstein I D, Thomas E D
Department of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, 98104.
Prog Clin Biol Res. 1990;333:403-10; discussion 411-3.
The ability to isolate large numbers of hematopoietic progenitors will facilitate an understanding of the growth and differentiation of bone marrow. Furthermore, isolating hematopoietic progenitors will have widespread clinical applications to autologous marrow transplantation, allogeneic marrow transplantation, gene therapy, and in vitro marrow expansion. With the development of avidin-biotin immunoadsorption, it is now feasible to isolate large numbers of these progenitor cells for clinical purposes. Successful hematopoietic reconstitution has been demonstrated in lethally irradiated baboons transplanted with CD34+ cells isolated by immunoadsorption with the anti-CD34 antibody 12-8. Recent studies have shown that CD34+ cells enriched from the marrow of patients with metastatic breast cancer can be used for autologous marrow transplantation.
分离大量造血祖细胞的能力将有助于理解骨髓的生长和分化。此外,分离造血祖细胞在自体骨髓移植、异体骨髓移植、基因治疗及体外骨髓扩增等方面将有广泛的临床应用。随着抗生物素蛋白-生物素免疫吸附技术的发展,现在为临床目的分离大量这些祖细胞已成为可能。用抗CD34抗体12-8免疫吸附分离出的CD34+细胞移植到经致死剂量照射的狒狒体内,已证明能成功实现造血重建。最近的研究表明,从转移性乳腺癌患者骨髓中富集的CD34+细胞可用于自体骨髓移植。